United States - English - NLM (National Library of Medicine)

fridda dorsch sl - ethyl methoxycinnamate (unii: sd418s06xd) (ethyl methoxycinnamate - unii:sd418s06xd), octocrylene (unii: 5a68wgf6wm) (octocrylene - unii:5a68wgf6wm), ethylhexyl triazone (unii: xqn8r9sak4) (ethylhexyl triazone - unii:xqn8r9sak4), titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp), bisoctrizole (unii: 8nt850t0ys) (bisoctrizole - unii:8nt850t0ys) -

United States - English - NLM (National Library of Medicine)

strides pharma science limited - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), sodium bicarbonate (unii: 8mdf5v39qo) (sodium cation - unii:lyr4m0nh37, bicarbonate ion - unii:hn1zra3q20), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698) - polyethylene glycol 3350 420 g in 4 l - polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution is indicated for bowel cleansing prior to colonoscopy in adults and pediatric patients aged 6 months or greater. polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution is contraindicated in the following conditions: - gastrointestinal (gi) obstruction, ileus, or gastric retention - bowel perforation - toxic colitis or toxic megacolon - known allergy or hypersensitivity to any component of polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution [see how supplied/storage and handling (16)] animal reproduction studies have not been conducted with polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution. it is also not known whether polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution can cause fetal harm when administered t

United States - English - NLM (National Library of Medicine)

novel laboratories, inc. - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p), sodium sulfate anhydrous (unii: 36kcs0r750) (sodium sulfate anhydrous - unii:36kcs0r750), sodium bicarbonate (unii: 8mdf5v39qo) (sodium cation - unii:lyr4m0nh37), sodium chloride (unii: 451w47iq8x) (chloride ion - unii:q32zn48698), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - polyethylene glycol 3350 236 g in 274.31 g - peg-3350 and electrolytes for oral solution is indicated for bowel cleansing prior to colonoscopy and barium enema x-ray examination in adults. peg-3350 and electrolytes for oral solution is contraindicated in the following conditions: - gastrointestinal (gi) obstruction (5.6) - bowel perforation (5.6) - toxic colitis or toxic megacolon - gastric retention - ileus - hypersensitivity to components of peg-3350 and electrolytes for oral solution (5.8) animal reproduction studies have not been conducted with peg-3350 and electrolytes for oral solution. it is also not known whether peg-3350 and electrolytes for oral solution can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. peg-3350 and electrolytes for oral solution should be given to a pregnant woman only if clearly needed. it is not known whether this drug is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when peg-3350 and electrolytes for oral solution is administ

United States - English - NLM (National Library of Medicine)

akorn - methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh) - methylene blue 10 mg in 1 ml - drug-induced methemoglobinemia. methylene blue can cause fetal harm when administered to a pregnant woman. an association exists between the use of methylene blue in amniocentesis and atresia of the ileum and jejunum, ileal occlusions and other adverse effects in the neonate. (2, 3) methylene blue is contraindicated in women who are or may become pregnant. if this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. intraspinal and subcutaneous injections are contraindicated. methylene blue is contraindicated in patients with a known hypersensitivity to the drug.

United States - English - NLM (National Library of Medicine)

general injectables & vaccines, inc - methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh) - methylene blue 10 mg in 1 ml - drug induced methemoglobinemia. methylene blue can cause fetal harm when administered to a pregnant woman. an association exists between the use of methylene blue in amniocentesis and atresia of the ileum and jejunum, ileal occlusions and other adverse effects in the neonate. (2, 3) methylene blue is contraindicated in women who are or may become pregnant. if this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. intraspinal and subcutaneous injections are contraindicated. methylene blue is contraindicated in patients with a known hypersensitivity to the drug.

United States - English - NLM (National Library of Medicine)

accord healthcare inc. - methyldopa (unii: 56lh93261y) (methyldopa anhydrous - unii:m4r0h12f6m) - methyldopa anhydrous 125 mg - hypertension. methyldopa is contraindicated in patients: - with active hepatic disease, such as acute hepatitis and active cirrhosis. - with liver disorders previously associated with methyldopa therapy (see warnings ). - with hypersensitivity to any component of this product. - on therapy with monoamine oxidase (mao) inhibitors.

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - methyldopa (unii: 56lh93261y) (methyldopa anhydrous - unii:m4r0h12f6m) - methyldopa anhydrous 250 mg - hypertension. methyldopa is contraindicated in patients:

United States - English - NLM (National Library of Medicine)

mylan institutional inc. - methyldopa (unii: 56lh93261y) (methyldopa anhydrous - unii:m4r0h12f6m) - methyldopa anhydrous 500 mg - hypertension. methyldopa is contraindicated in patients: - with active hepatic disease, such as acute hepatitis and active cirrhosis. - with liver disorders previously associated with methyldopa therapy (see warnings). - with hypersensitivity to any component of this product. - on therapy with monoamine oxidase (mao) inhibitors.

United States - English - NLM (National Library of Medicine)

rebel distributors corp - methyldopa (unii: 56lh93261y) (methyldopa anhydrous - unii:m4r0h12f6m) - methyldopa anhydrous 250 mg - hypertension. methyldopa is contraindicated in patients: - with active hepatic disease, such as acute hepatitis and active cirrhosis. - with liver disorders previously associated with methyldopa therapy (see warnings ). - with hypersensitivity to any component of this product. - on therapy with monoamine oxidase (mao) inhibitors.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - methyldopa (unii: 56lh93261y) (methyldopa - unii:56lh93261y) - methyldopa 250 mg - hypertension. methyldopa is contraindicated in patients: - with active hepatic disease, such as acute hepatitis and active cirrhosis. - with liver disorders previously associated with methyldopa therapy (see warnings ). - with hypersensitivity to any component of this product. - on therapy with monoamine oxidase (mao) inhibitors.